Lipoprotein(a) and ApoB: Two Important Markers of Cardiovascular Risk

Written By Daniel Placik

For many years, LDL cholesterol (“bad cholesterol”) has been the primary focus of cardiovascular risk assessment. While LDL cholesterol remains important, research increasingly shows that other lipid markers may provide a more accurate picture of cardiovascular risk in certain individuals.

Two of the most important markers are:

  • Lipoprotein(a), or Lp(a)

  • Apolipoprotein B, or apoB

Both are independent and causal risk factors for atherosclerotic cardiovascular disease (ASCVD), but they measure different aspects of cardiovascular risk.

Understanding the difference between them can help identify risk that standard cholesterol panels may miss.

What is Lp(a)?

Lipoprotein(a), or Lp(a), is a specialized LDL-like particle.

It contains:

  • An LDL particle

  • ApoB-100

  • An additional protein called apolipoprotein(a), or apo(a)

This unique structure gives Lp(a) several harmful properties:

  • Pro-atherogenic (promotes plaque formation)

  • Pro-inflammatory

  • Pro-thrombotic (promotes clotting)

Lp(a) also carries oxidized phospholipids, which may further contribute to vascular inflammation and plaque instability.

Lp(a) is largely genetic

Unlike many other cholesterol markers, Lp(a) levels are determined primarily by genetics.

About 70–90% of variation in Lp(a) levels is inherited through the LPA gene.

Levels can vary dramatically between individuals:

  • Some people have levels near zero

  • Others have extremely high levels

Importantly:

  • Diet has little effect

  • Exercise has little effect

  • Weight loss usually has minimal effect

This is why someone with an otherwise healthy lifestyle may still have elevated cardiovascular risk due to high Lp(a).

Why does Lp(a) matter?

Research strongly supports Lp(a) as a causal cardiovascular risk factor.

Elevated Lp(a) has been associated with:

  • Coronary artery disease

  • Heart attack

  • Stroke

  • Aortic valve stenosis

  • Heart failure

This association remains significant even after accounting for:

  • LDL cholesterol

  • Blood pressure

  • Smoking

  • Diabetes

What level is considered high?

Risk is generally considered elevated at:

  • ≥50 mg/dL
    or

  • ≥125 nmol/L

However, some evidence suggests risk may begin increasing above:

  • 30 mg/dL

Approximately 20–25% of the global population has elevated Lp(a).

Should everyone be tested?

Many experts now recommend measuring Lp(a) at least once in adulthood.

Several international guidelines support this approach because:

  • Levels are largely genetic

  • Levels remain relatively stable over life

  • Elevated levels may change treatment decisions

The ACC/AHA guidelines also consider elevated Lp(a) a “risk-enhancing factor” when deciding whether to start statin therapy.

Can Lp(a) be lowered?

Currently, treatment options are limited.

Statins

Statins generally:

  • Do not lower Lp(a)

  • May slightly increase it

However, statins still reduce cardiovascular risk overall and remain important when otherwise indicated.

PCSK9 inhibitors

These medications can reduce Lp(a) by approximately:

  • 20–25%

But it is still unclear how much this reduction specifically lowers Lp(a)-related risk.

Emerging therapies

Several new medications are currently in advanced clinical trials, including:

  • Pelacarsen

  • Olpasiran

  • SLN360

These drugs target apo(a) production in the liver and can reduce Lp(a) levels by:

  • More than 80%

These therapies may significantly change cardiovascular prevention in the future.

What is ApoB?

ApoB is very different from Lp(a).

ApoB is the main structural protein found on all atherogenic lipoproteins, including:

  • LDL

  • VLDL

  • IDL

  • Lp(a)

  • Chylomicron remnants

Each atherogenic particle contains exactly:

  • One apoB molecule

This means apoB directly measures:

  • The total number of circulating atherogenic particles

Why is apoB important?

LDL cholesterol measures:

  • The amount of cholesterol inside LDL particles

ApoB measures:

  • The number of atherogenic particles themselves

This distinction matters because:

  • Two people can have the same LDL cholesterol

  • But very different numbers of LDL particles

More particles generally means:

  • Greater plaque formation risk

ApoB may be more accurate than LDL cholesterol

Research increasingly suggests apoB may predict cardiovascular risk better than LDL cholesterol alone.

In some studies:

  • When apoB and LDL-C were analyzed together

  • ApoB remained strongly associated with heart attack risk

  • LDL-C did not

When does apoB become especially useful?

ApoB is particularly valuable when LDL cholesterol may underestimate risk.

This commonly occurs in:

  • Diabetes

  • Metabolic syndrome

  • Elevated triglycerides

  • Cardiometabolic kidney syndrome (CKM)

In these situations:

  • LDL cholesterol may appear “normal”

  • But apoB remains elevated

This is called:

  • “Discordance”

ApoB helps identify residual risk in these patients.

ApoB targets

The National Lipid Association suggests apoB goals of:

  • ≤60 mg/dL → very high risk

  • ≤70 mg/dL → high risk

  • ≤90 mg/dL → borderline/intermediate risk

ApoB testing is also:

  • Well standardized

  • Reliable

  • Not affected by fasting

How are Lp(a) and ApoB related?

Lp(a) itself contains apoB.

This means:

  • Elevated Lp(a) contributes to total apoB concentration

However, the two tests provide different information.

Why measuring both matters

ApoB measures:

  • Total atherogenic particle burden

Lp(a) identifies:

  • A specific genetically driven particle with particularly high risk

Recent research suggests Lp(a) may be:

  • Approximately 7 times more atherogenic than LDL on a per-particle basis

This means standard apoB measurements may underestimate risk in people with very high Lp(a).

Practical takeaways

Lp(a)

  • Primarily genetic

  • Helps identify inherited cardiovascular risk

  • Usually measured once in adulthood

ApoB

  • Measures total atherogenic particle burden

  • Often more informative than LDL cholesterol alone

  • Especially useful in metabolic disease

Bottom line

Lp(a) and apoB are two of the most important modern cardiovascular risk markers.

They measure different but complementary aspects of cardiovascular risk:

  • ApoB reflects the total number of atherogenic particles

  • Lp(a) identifies a uniquely harmful genetically driven lipoprotein

For many individuals, especially those with:

  • Premature family history of heart disease

  • Diabetes

  • Elevated triglycerides

  • Metabolic syndrome

  • “Normal” LDL cholesterol but persistent concern

Measuring both markers may provide a much more complete understanding of cardiovascular risk than a standard cholesterol panel alone.

As research continues and new therapies emerge, these markers will likely play an increasingly important role in preventive cardiology and longevity-focused medicine.

Daniel Placik
Next

Are Seed Oils Bad for You? What the Evidence Actually Shows